BIO-key International, Inc. Reports 18% Revenue Growth in Q3 2024 and Improved Financial Performance
BIO-key International, Inc. Reports 18% Revenue Growth in Q3 2024 and Improved Financial Performance
BIO-key International reported Q3'24 revenue of $2.1M, an 18% increase, with reduced net loss and improved gross profit.
BIO-key International报告2024财年第三季度营业收入为$2.1 million,增长18%,净损失减少,毛利提高。
Quiver AI Summary
Quiver AI 概要
BIO-key International, Inc. reported its third quarter financial results for 2024, showing an 18% increase in revenues, reaching $2.1 million, primarily due to higher license revenue from existing customers. The company's gross profit significantly improved to $1.7 million with a gross margin of 78.3%, contrasted with a low margin in the previous year, aided by reduced costs and an absence of hardware reserves previously recorded. Despite a net loss of $0.7 million, the loss was an improvement compared to $1.8 million in Q3 2023. BIO-key also highlighted significant customer orders and partnerships, including a notable upgrade order from a financial services customer, emphasizing its strong market position and potential for future growth. Looking ahead, the company anticipates revenues for the full year 2024 to meet or exceed previous figures while continuing efforts to reduce costs and improve cash flow. An investor call is scheduled for November 15 to discuss the results.
BIO-key International报告了截至2024年第三季度的财务业绩,显示营收增长18%,达到$2.1 million,主要是由于现有客户授权收入增加。公司的毛利大幅提高至$1.7 million,毛利率为78.3%,与前一年低毛利相比有显著改善,得益于成本降低和之前记录的硬件准备金不再计入。尽管净损失为$0.7 million,但与2023年第三季度的$1.8 million相比有所改善。BIO-key还突出了重大客户订单和合作伙伴关系,包括来自一家金融服务客户的显著升级订单,强调其在市场上的强势地位和未来增长潜力。展望未来,该公司预计2024全年营收将达到或超过之前的数字,同时继续努力降低成本和改善现金流。投资者电话会议定于11月15日讨论业绩。
Potential Positives
潜在的积极因素
- Q3'24 revenues rose 18% year-over-year to $2.1M, primarily driven by a significant increase in license revenue.
- Gross profit improved to $1.7M with a gross margin of 78.3%, showcasing a substantial shift in profitability compared to the same quarter last year.
- The company successfully reduced operating expenses by $46,000, indicating effective cost management strategies.
- BIO-key secured significant contracts, including a $910k order from a long-time customer and a $500k follow-on order from a defense ministry, highlighting strong demand for its solutions.
- 2024财年第三季度营收同比增长18%,达到$2.1 million,主要受到授权收入大幅增加的推动。
- 毛利提高至$1.7 million,毛利率为78.3%,较去年同期有实质性盈利能力转变。
- 公司成功减少营业费用$46,000,表明有效的成本管理策略。
- BIO-key获得重大合同,包括一份长期客户的价值$910,000的订单以及一份来自国防部的后续订单价值$500,000,凸显其解决方案的强劲需求。
Potential Negatives
潜在负面影响
- Despite a year-over-year revenue increase, total revenues for the nine months ended September 30, 2024, decreased compared to the same period in 2023, indicating an overall decline in performance.
- The company experienced a loss of a large recurring service agreement and a significant customization customer, which negatively affected service revenues.
- Continued reliance on warrant inducement agreements to raise capital indicates potential financial instability and reliance on unconventional funding methods.
- 尽管从年度收入增长,截至2024年9月30日的九个月总收入与2023年同期相比有所下降,表明绩效总体下降。
- 公司经历了一笔大额经常性服务协议和一个重要定制客户的流失,对服务收入产生了负面影响。
- 继续依赖权证诱因协议筹集资本,表明潜在的财务不稳定性和对非传统筹款方法的依赖。
FAQ
FAQ
What are BIO-key's Q3 2024 revenue results?
bio-key international的2024年第三季度营收结果是什么?
BIO-key reported Q3 2024 revenues of $2.1M, an 18% increase from $1.8M in Q3 2023, driven by license revenue growth.
bio-key international报告2024年第三季度营收为210万美元,比2013年第三季度的180万美元增长了18%,这得益于许可收入增长。
How did gross profit change in Q3 2024?
2024年第三季度,毛利润发生了什么变化?
Gross profit improved to $1.7M in Q3 2024, reflecting a 78.3% gross margin, up from $0.3M in the prior year.
毛利润在2024年第三季度提高至170万美元,毛利率为78.3%,高于前一年的30万美元。
What were the key highlights for BIO-key after Q3 2024?
2024年第三季度后的BIO-key主要亮点是什么?
Key highlights include a $910k order for financial services, a $500k defense contract, and 10,000 additional users in British Columbia.
主要亮点包括金融服务的91万美元订单,50万美元的国防合同,以及在不列颠哥伦比亚省增加了1万名用户。
When will BIO-key host its investor call?
BIO-key将在何时举行投资者电话会议?
BIO-key will host an investor call on November 15, 2024, at 10:00 AM ET to discuss these results.
BIO-key将于2024年11月15日上午10:00(东部时间)举行投资者电话会议,讨论这些结果。
What is BIO-key's outlook for the full year 2024?
BIO-key对2024年全年的展望如何?
BIO-key expects full year 2024 revenues to meet or exceed the $7.75M achieved in 2023, focusing on high-margin revenue streams.
BIO-key预计2024年全年的营业收入将达到或超过2023年的775万美元,专注于高利润的营收领域。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免责声明:这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。
$BKYI Hedge Fund Activity
BKYI对冲基金活动
We have seen 4 institutional investors add shares of $BKYI stock to their portfolio, and 5 decrease their positions in their most recent quarter.
我们看到有4家机构投资者在最近一个季度向其投资组合中增加了$BKYI股票的数量,而有5家减少了他们的持股。
Here are some of the largest recent moves:
以下是一些最近最大的交易动态:
- ARMISTICE CAPITAL, LLC added 250,000 shares (+inf%) to their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC removed 12,108 shares (-100.0%) from their portfolio in Q3 2024
- UBS GROUP AG added 2,005 shares (+454.6%) to their portfolio in Q2 2024
- TOWER RESEARCH CAPITAL LLC (TRC) removed 714 shares (-12.1%) from their portfolio in Q3 2024
- GROUP ONE TRADING, L.P. removed 334 shares (-100.0%) from their portfolio in Q2 2024
- WELLS FARGO & COMPANY/MN added 39 shares (+1300.0%) to their portfolio in Q3 2024
- ABICH FINANCIAL WEALTH MANAGEMENT LLC removed 37 shares (-100.0%) from their portfolio in Q3 2024
- 爱文思控股公司在2024年第三季度将25万股(+inf%)加入其投资组合
- GEODE CAPITAL MANAGEMENt, LLC在2024年第三季度从其投资组合中减少了12,108股(-100.0%)
- 瑞银增加了2,005股(+454.6%)至其2024年第二季度投资组合
- 特斯拉-仪表研究资本有限责任公司(TRC)在2024年第三季度将714股(-12.1%)从其投资组合中删除
- Group One Trading,L.P.在2024年第二季度从其投资组合中减少了334股(-100.0%)
- 富国银行公司在2024年第三季度向其投资组合增加了39股(+1300.0%)
- ABICH金融财富管理有限公司在2024年第三季度从其投资组合中剔除37股(-100.0%)
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要追踪对冲基金的股票组合,请查看Quiver Quantitative的机构持股仪表板。
Full Release
全面发布
HOLMDEL, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) --
BIO-key
International, Inc.
(Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its third quarter ended September 30, 2024 (Q3'24). BIO-key's 2023 Q3 and nine month results were restated and filed with the Company's
2023 Form 10-K
and are reflected in this release. BIO-key will host an investor call tomorrow, Friday, November 15th at 10:00am ET (details below).
2024年11月14日,新泽西州霍尔姆德尔(HOLMDEL)(GLOBE NEWSWIRE)
生物密钥
国际公司,股份有限公司
(纳斯达克:BKYI),一家创新的劳工和客户身份和访问管理(IAM)解决方案的提供商,涵盖了无密码、无手机和无令牌的身份绑定生物识别(IBB)认证,宣布截至2024年9月30日的第三季度(Q3'24)的业绩。生物密钥的2023年第三季度和前九个月的业绩已经重新规定并提交给该公司
2023年10-K表格
这些内容已反映在此版本中。 BIO-key将于明天主持投资者电话,即11月15日星期五上午10:00 Et(详细信息如下)。
Financial Highlights
财务亮点
-
Q3'24 revenues rose 18% to $2.1M from $1.8M in Q3'23, principally due to a $0.5M increase in license revenue related to expanded software deployments by long-term customers.
-
Gross profit improved to $1.7M (78.3% gross margin) in Q3'24 vs. $0.3M (18.7% gross margin) in Q3'23, due to an increase in high-margin license revenue, lower costs to support deployments, and a $1M hardware reserve taken in the prior-year period.
-
BIO-key trimmed Q3'24 operating expenses by $46,000 versus Q3'23, reflecting proactive reductions in administration, sales personnel costs and marketing show expenses, offset by higher professional services expenses principally related to financing activities.
-
BIO-key reported a Q3'24 net loss of $0.7M compared to a Q3'23 net loss of $1.8M, due primarily to an increase in high-margin license revenue, level operating expenses, and the prior-year hardware reserve.
-
Cash used in operating activities was $2.4M through the first nine months of 2024 vs. $2.3M in the prior-year period. The current-year period reflects BIO-key's net loss through the first nine months and positive adjustments for non-cash expenses of approximately $667,000.
-
2024年第三季度营收同比增长18%,从第三季度23的180万美元增至210万美元,主要是由于长期客户扩大软件部署导致的许可收入增加50万美元。
-
2024财年第三季度毛利润提升至170万美元(78.3%毛利率),相比第23财年第三季度的30万美元(18.7%毛利率),主要是由于高毛利的许可收入增加,支持部署成本降低,以及在前一年度期间提取的100万美元硬件准备金。
-
BIO-key将第三财季营业费用削减46,000美元,与第三财季23相比,主要体现了管理、销售人员成本和市场费用的积极降低,但由于专业服务费用增加,主要与融资活动相关。
-
与第三财季23相比,BIO-key第三财季24净亏损为70万美元,而第23财季净亏损为180万美元,主要原因是高毛利许可收入增加,营业费用保持稳定,以及前一年度硬件准备金。
-
2024年前九个月营运活动中的现金使用额为240万美元,而前一年同期为230万美元。本年度前九个月反映了BIO-key的净亏损和约667,000美元的非现金费用的积极调整。
Recent Highlights
最近的亮点
-
Following the close of Q3'24,
BIO-key Secured a $910k Order
to Upgrade a Long-time Financial Services Customer to its Enhanced Biometric Customer Identification Technology
-
A
Leading International Defense Ministry Awarded BIO-key $500k in Follow-On Order
s
for Biometric User Authentication
-
British Columbia Added 10,000 Users to its BIO-key Biometric Solution Deployment
for Sign-on and Physical Access Control
-
BIO-key's PortalGuard Identity and Access Management Solution and Identity-Bound Biometrics Became
Available on the Amazon Web Services (AWS) Marketplace
-
Williamsburg, VA
advanced its Zero Trust initiative with BIO-key's Identity-Bound Biometrics.
-
BIO-key Raised $1.9M in Gross Proceeds via
Warrant Inducement
-
在2024年第三季度结束后,
bio-key international赢得了91万美元的订单
将长期金融服务客户升级到其增强的生物识别客户身份验证技术
-
A
领先国际国防部向BIO-key授予50万美元的跟单订单
s
用于生物识别用户身份验证
-
不列颠哥伦比亚省在其BIO-key生物特征解决方案部署中增加了10,000个用户
用于登录和物理访问控制
-
BIO-key的PortalGuard身份和访问管理解决方案与身份绑定生物识别技术变得
可在亚马逊网络服务(AWS)市场上获取
-
威廉斯堡,弗吉尼亚州
通过BIO-key的身份绑定生物识别技术,加快了其零信任计划。
-
BIO-key通过募集190万美元的毛收入金额
认股权诱因
Commentary
BIO-key CEO, Mike DePasquale commented, "We had a very productive third quarter, with revenue increasing 18% year-over-year and $1M compared to Q2'24, supported by license fee revenue which rose to $1.4M in Q3'24 from $1.0M in Q3'23. Our Q3'24 revenues reflected strength in orders from existing customers who are expanding their deployment of BIO-key solutions. This momentum continued into Q4 with an exciting order from a long-time foreign financial services customer to utilize our biometric identification technology for customer identification within their branches.
评论
BIO-key CEO, Mike DePasquale commented, "We had a very productive third quarter, with revenue increasing 18% year-over-year and $100万 compared to Q2'24, supported by license fee revenue which rose to $140万 in Q3'24 from $100万 in Q3'23. Our Q3'24 revenues reflected strength in orders from existing customers who are expanding their deployment of BIO-key solutions. This momentum continued into Q4 with an exciting order from a long-time foreign financial services customer to utilize our biometric identification technology for customer identification within their branches.
"This firm has already enrolled the fingerprint biometrics of over 25M of its customers using BIO-key technology as part of its know your customer (KYC) process. They are now upgrading to BIO-key's "fingerprint only" identification solution which will enable them to identify each of their customers with just a fingerprint scan, eliminating the need for a bank card, account or ID number. This highly secure and efficient identification approach is expected to save an estimated thirty seconds per client encounter, benefiting both customers and bank personnel.
"This firm has already enrolled the fingerprint biometrics of over 2500万 of its customers using BIO-key technology as part of its know your customer (KYC) process. They are now upgrading to BIO-key's "fingerprint only" identification solution which will enable them to identify each of their customers with just a fingerprint scan, eliminating the need for a bank card, account or ID number. This highly secure and efficient identification approach is expected to save an estimated thirty seconds per client encounter, benefiting both customers and bank personnel.
"We believe this is one of the world's largest deployments of one-to-many biometric technology in a private commercial or enterprise setting, as compared to one-to-one matching of a fingerprint scan with a biometric associated with an account, ID number or card. Working with the client and our partner at AWS, we intend to publish a more detailed whitepaper on this deployment to fully explain the unique benefits our advanced biometric identity solutions can provide to other enterprises. We are of course very excited about this large-scale adoption of our technology and look to leverage the value and benefits of use in this example for our direct and Channel Alliance Partner (CAP) sales programs.
"We believe this is one of the world's largest deployments of one-to-many biometric technology in a private commercial or enterprise setting, as compared to one-to-one matching of a fingerprint scan with a biometric associated with an account, ID number or card. Working with the client and our partner at AWS, we intend to publish a more detailed whitepaper on this deployment to fully explain the unique benefits our advanced biometric identity solutions can provide to other enterprises. We are of course very excited about this large-scale adoption of our technology and look to leverage the value and benefits of use in this example for our direct and Channel Alliance Partner (CAP) sales programs.
"Given the nature of our size and the timing and impact of larger customer orders, we do expect our performance to vary on a quarter-to-quarter basis as we build a growing base of high-margin, annually recurring revenue streams from software licenses and services. We expect full year 2024 revenues to meet or exceed the $7.75M achieved in 2023, and we continue to pursue opportunities to lower our overhead and variable costs, as we progress the business toward positive operating cash flow and profitability in the coming quarters. Additionally, we continue to seek potential strategic opportunities that can leverage our core strengths and business platform to create value for our shareholders.
"Given the nature of our size and the timing and impact of larger customer orders, we do expect our performance to vary on a quarter-to-quarter basis as we build a growing base of high-margin, annually recurring revenue streams from software licenses and services. We expect full year 2024 revenues to meet or exceed the $775万 achieved in 2023, and we continue to pursue opportunities to lower our overhead and variable costs, as we progress the business toward positive operating cash flow and profitability in the coming quarters. Additionally, we continue to seek potential strategic opportunities that can leverage our core strengths and business platform to create value for our shareholders.
"From a financial perspective, we were able to raise $1.9M during the third quarter through a warrant inducement agreement, pursuant to which an existing institutional investor exercised warrants to purchase 1,030,556 BIO-key shares at $1.85 per share. Reflecting these proceeds, our cash position improved to $1.8M at close of Q3'24 vs. $0.5M at year end 2023."
从财务角度来看,我们通过认股权诱因协议在第三季度成功筹集了190万美元,根据该协议,一位现有机构投资者行使认股权,以每股1.85美元的价格购买1030556股BIO-key股票。反映这些收入,我们的现金状况在2024年第3季度结束时改善至180万美元,而在2023年年底为50万美元。
Financial Results
BIO-key's Q3'24 revenues increased 18% to $2.1M from $1.8M in Q3'23. License revenue increased $491,000 or 52% to $1.4M and hardware sales increased 56% to $436,000, as several long-term customers expanded their license deployments and purchased additional biometric readers. Declines in recurring and non-recurring service revenues of $320,522 stemmed from the loss of one large recurring service agreement and one large customization customer from the prior-year period. For the nine months ended September 30, 2024, revenues were $5.5M compared to $5.9M in the comparable 2023 period, as increased license fees and hardware revenue was offset by lower service revenues.
财务结果
BIO-key的2024年第3季度营收同比增长18%,达到210万美元,较2023年第3季度的180万美元有所增加。许可证营收增加了491,000美元,增长了52%,达到140万美元,硬件销售增长了56%,达到436,000美元,因为几位长期客户扩大了许可部署,并购买了更多生物识别读卡器。320,522美元的经常性和非经常性服务收入下降是由于失去了一个大型经常性服务协议和一个大型客户定制客户所致。截至2024年9月30日的九个月内,收入为550万美元,而在可比的2023年同期为590万美元,增加的许可费和硬件收入被较低的服务收入抵消。
Q3'24 Gross profit was $1.7M (78.3% gross margin) versus $0.3M (18.7% gross margin) in Q3'23, primarily reflecting the impact of a $1M hardware reserve in Q3'23, a higher proportion of high margin license fee revenue in Q3'24, and lower costs to support deployments, including license fees for third-party software included in BIO-key's Swivel Secure offerings.
2024年第3季度的毛利为170万美元(毛利率78.3%),而2023年第3季度为30万美元(毛利率18.7%),主要反映了2023年第3季度100万美元的硬件准备金的影响,2024年第3季度高毛利许可费收入比例更高,以及降低支持部署的成本,包括BIO-key Swivel Secure产品中包含的第三方软件的许可费降低。
BIO-key trimmed operating expenses by $46,000 in Q3'24 versus Q3'23, reflecting reductions in administration expenses, including lower headquarters expense, sales personnel costs, and marketing show expenses, partially offset by an increase in professional services, principally related to the Company's financing activities. Also offsetting lower SG&A costs was a $122,000 increase in research, development and engineering expense due to increased personnel costs to support new product development.
与2023年第3季度相比,BIO-key在2024年第3季度将营业费用削减了46,000美元,反映出管理费用的降低,包括较低的总部费用、销售人员成本以及市场展示费用,部分抵消了专业服务费用的增加,主要与公司的融资活动有关。抵消销售和管理费用下降的还有研发费用增加122,000美元,主要是由于增加的人员成本支持新产品开发。
Reflecting higher revenue and gross profit and flat operating expenses, BIO-key's net loss improved to $0.7M, or $0.39 per share, in Q3'24, from a net loss of $1.8M, or $3.22 per share, in Q3'23. Likewise, BIO-key reduced its net loss for the first nine months of 2024 to $2.9M, or $1.69 per share, compared to a net loss of $6.1M, or $10.79 per share, in the first nine months of 2023. Q3'23 results included the hardware reserve of $1.0M and the first nine months of 2023 included a hardware reserve of $2.5M.
反映出收入和毛利的增加以及营业费用持平,BIO-key在2024年第3季度的净亏损从2023年第3季度的180万美元,或每股3.22美元,改善至70万美元,或每股0.39美元。同样,BIO-key将2024年头9个月的净亏损降至290万美元,或每股1.69美元,而在2023年头9个月是610万美元,或每股10.79美元。2023年第3季度的结果包括100万美元的硬件准备金,而2023年头9个月包括250万美元的硬件准备金。
Balance Sheet
At September 30, 2024, BIO-key had current assets of approximately $4.6M, including $1.8M of cash and cash equivalents, $2.0M of net accounts receivable and due from factor, and $387,000 of inventory. This compares to current assets of $2.6M at December 31, 2023, including approximately $511,000 of cash equivalents, $1.3M of net accounts receivable and due from factor, and $446,000 of inventory.
资产负债表:
截至2024年9月30日,BIO-key的流动资产约为460万美元,包括180万美元的现金及现金等价物,200万美元的净应收账款和应收因素,及387,000美元的存货。与2023年12月31日的流动资产260万美元相比,后者包括约511,000美元的现金等价物,130万美元的净应收账款和应收因素以及446,000美元的存货。
Conference Call Details | ||
Date / Time: |
Friday, November 15th at 10 a.m. ET |
|
Call Dial In #: |
1-877-418-5460 U.S. or 1-412-717-9594 Int'l |
|
Live Webcast / Replay: |
Webcast & Replay Link – Available for 3 months. |
|
Audio Replay: |
1-877-344-7529 U.S. or 1-412-317-0088 Int'l; code 7307131 |
电话会议详情 | ||
日期/时间: |
周五,11月15日 在 美东时间上午10点 |
|
看涨拨号号码: |
美国电话:1-877-418-5460,国际电话:1-412-717-9594 |
|
直播网络广播 / 重播: |
网络广播及重播链接 – 提供3个月。 |
|
音频回放: |
美国:1-877-344-7529;国际:1-412-317-0088;密码7307131 |
About BIO-key International, Inc. (
)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
关于bio-key international公司(
)
BIO-key正在通过生物识别中心的多因素身份和访问管理(iam)软件革新身份验证和网络安全,为超过四千万用户提供安全访问。BIO-key允许客户根据不同的使用案例选择合适的身份验证因素,包括无手机、无需令牌和无密码的生物识别选项。其托管或本地的PortalGuard iam解决方案提供经济高效、易于部署、方便和安全的计算机、信息、应用程序以及高价值交易的访问。
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence the restatement of our financial statements, including any consequences of non-compliance with Securities and Exchange Commission and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; if we fail to increase our stockholders' equity to at least $2.5 million, our common stock will be delisted from the Nasdaq Capital Market which could negatively impact the trading price of our common stock and impair our ability to raise capital, any disruption to our business that may occur on a longer-term basis should we be unable to remediate during fiscal year 2024 certain material weaknesses in our internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
BIO-key安全港声明
本新闻稿中包含的所有声明,除了历史事实陈述之外,均属于1995年《私人证券诉讼改革法案》("法案")定义的"前瞻性陈述"。"估计," "计划," "打算," "期望," "预计," "相信" 等类似表达旨在识别前瞻性声明。此类前瞻性声明是基于管理层的信念,并根据管理层根据法案"安全港"条款所作的假设和当前可获得的信息。这些声明并非未来绩效或事件的保证,可能受到风险和不确定性的影响,这些风险和不确定性可能导致实际结果与此类前瞻性声明所包含的结果有实质差异,或受到暗示。这些风险和不确定性包括但不限于我们的亏损历史和有限营收;我们筹集额外资本以满足营运资本需求的能力;我们作为持续存续实体的能力;我们保护知识产权的能力;商业条件的变化;我们销售策略和产品开发计划的变化;市场的变化;我们执行管理团队的继续服务;安全漏洞;生物识别技术行业的竞争;生物识别产品普遍受市场认可和我们开发中产品的市场认可度;我们能否将销售机会转化为客户合同;我们能否拓展至亚洲、非洲和其他外国市场;我们能否将Swivel Secure的运营和人员整合到我们的业务;外汇汇率波动;产品开发的延迟;商业、声誉和监管风险可能会导致我们财务报表重新编制,包括不符合证券交易委员会和纳斯达克定期报告要求的任何后果;如果我们未能将我们的股东权益增加至至少250万美元,我们的普通股将从纳斯达克资本市场摘牌,可能会对我们的普通股交易价格造成负面影响,并损害我们筹集资本的能力,若我们无法在2024财年期间修正我们财务报告内部控制某些重大缺陷,则在较长期内可能会对我们业务造成任何干扰。未纳入任何上述陈述的假设,以及其他因素列在我们于2023年12月31日结束的年度10-K报告"风险因素"标题下,以及我们向证券交易委员会提交的其他文件中。读者被告诫不要过分依赖这些前瞻性陈述,这些陈述仅在制作日期有效。除法律要求外,我们不承诺对这些前瞻性陈述进行任何修订,无论是因新信息、未来事件,还是其他原因。
Engage with BIO-key | ||
Facebook – Corporate: |
|
|
LinkedIn – Corporate: |
|
|
X – Corporate: |
@BIOkeyIntl |
|
X – Investors: |
@BIO_keyIR |
|
StockTwits: |
BIO_keyIR |
与bio-key互动 | ||
Facebook公司页面: |
|
|
Linkedin公司页面: |
|
|
X – 公司: |
@bio-key international |
|
X – 投资者: |
@BIO_keyIR |
|
StockTwits: |
BIO_keyIR |
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com
or 212-924-9800
投资者联系方式
William Jones,David Collins
Catalyst IR
BKYI@catalyst-ir.com
或者212-924-9800
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | ||||||||||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||
September 30, |
September 30, |
|||||||||||||||
2024 |
2023 |
2024 |
2023 |
|||||||||||||
Revenues |
||||||||||||||||
Services |
$ |
267,371 |
$ |
587,893 |
$ |
764,062 |
$ |
1,740,880 |
||||||||
License fees |
1,441,011 |
950,015 |
4,165,669 |
3,764,342 |
||||||||||||
Hardware |
436,422 |
279,200 |
537,562 |
424,582 |
||||||||||||
Total revenues |
2,144,804 |
1,817,108 |
5,467,293 |
5,929,804 |
||||||||||||
Costs and other expenses |
||||||||||||||||
Cost of services |
110,723 |
125,039 |
322,957 |
639,996 |
||||||||||||
Cost of license fees |
146,732 |
253,891 |
443,384 |
1,022,919 |
||||||||||||
Cost of hardware |
207,655 |
97,674 |
260,684 |
240,074 |
||||||||||||
Cost of hardware - reserve |
- |
1,000,000 |
- |
2,500,000 |
||||||||||||
Total costs and other expenses |
465,110 |
1,476,604 |
1,027,025 |
4,402,989 |
||||||||||||
Gross profit |
1,679,694 |
340,504 |
4,440,268 |
1,526,815 |
||||||||||||
Operating Expenses |
||||||||||||||||
Selling, general and administrative |
1,607,925 |
1,776,305 |
5,332,764 |
5,851,201 |
||||||||||||
Research, development and engineering |
652,174 |
529,757 |
1,850,929 |
1,778,097 |
||||||||||||
Total Operating Expenses |
2,260,099 |
2,306,062 |
7,183,693 |
7,629,298 |
||||||||||||
Operating loss |
(580,405 ) |
(1,965,558 ) |
(2,743,425 ) |
(6,102,483 ) |
||||||||||||
Other income (expense) |
||||||||||||||||
Interest income |
2 |
5,917 |
53 |
5,944 |
||||||||||||
Loss on foreign currency transactions |
- |
- |
- |
(15,000 ) |
||||||||||||
Loan fee amortization |
(60,000 ) |
- |
(64,000 ) |
- |
||||||||||||
Change in fair value of convertible note |
- |
167,283 |
- |
264,706 |
||||||||||||
Interest expense |
(98,556 ) |
(45,655 ) |
(108,823 ) |
(159,380 ) |
||||||||||||
Total other income (expense), net |
(158,554 ) |
127,545 |
(172,770 ) |
96,270 |
||||||||||||
Loss before provision for income tax |
(738,959 ) |
(1,838,013 ) |
(2,916,195 ) |
(6,006,213 ) |
||||||||||||
Provision for (income tax) tax benefit |
- |
189 |
- |
(142,811 ) |
||||||||||||
Net loss |
$ |
(738,959 ) |
$ |
(1,837,824 ) |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||||||
Comprehensive loss: |
||||||||||||||||
Net loss |
$ |
(738,959 ) |
$ |
(1,837,824 ) |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||||||
Other comprehensive income (loss) – Foreign currency translation adjustment |
89,933 |
35,364 |
51,878 |
127,394 |
||||||||||||
Comprehensive loss |
$ |
(649,026 ) |
$ |
(1,802,460 ) |
$ |
(2,864,317 ) |
$ |
(6,021,630 ) |
||||||||
Basic and Diluted Loss per Common Share |
$ |
(0.39 ) |
$ |
(3.22 ) |
$ |
(1.69 ) |
$ |
(10.79 ) |
||||||||
Weighted Average Common Shares Outstanding: |
|
|
|
|
||||||||||||
Basic and diluted |
1,889,694 |
570,753 |
1,726,716 |
569,882 |
||||||||||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key's 1-for-18 reverse stock split, which was effective December 21, 2023. |
bio-key international公司及其子公司 综合损失及综合损益简明综合表 (未经审计) | ||||||||||||||||
截至三个月 |
截至九个月 |
|||||||||||||||
9月30日, |
9月30日, |
|||||||||||||||
2024 |
2023 |
2024 |
2023 |
|||||||||||||
收入 |
||||||||||||||||
服务 |
$ |
267,371 |
$ |
587,893 |
$ |
764,062 |
$ |
1,740,880 |
||||||||
许可证费用 |
1,441,011 |
950,015 |
4,165,669 |
3,764,342 |
||||||||||||
硬件 |
436,422 |
279,200 |
537,562 |
424,582 |
||||||||||||
总收入 |
2,144,804 |
1,817,108 |
5,467,293 |
5,929,804 |
||||||||||||
成本及其他费用 |
||||||||||||||||
服务成本 |
110,723 |
125,039 |
322,957 |
639,996 |
||||||||||||
许可费用 |
146,732 |
253,891 |
443,384 |
1,022,919 |
||||||||||||
硬件成本 |
207,655 |
97,674 |
260,684 |
240,074 |
||||||||||||
硬件成本 - 储备 |
- |
1,000,000 |
- |
2,500,000 |
||||||||||||
总成本和其他费用 |
465,110 |
1,476,604 |
1,027,025 |
4,402,989 |
||||||||||||
毛利润 |
1,679,694 |
340,504 |
4,440,268 |
1,526,815 |
||||||||||||
运营费用 |
||||||||||||||||
销售、一般及行政费用 |
1,607,925 |
1,776,305 |
5,332,764 |
5,851,201 |
||||||||||||
研究、开发和工程 |
652,174 |
529,757 |
1,850,929 |
1,778,097 |
||||||||||||
总营业费用 |
2,260,099 |
2,306,062 |
7,183,693 |
7,629,298 |
||||||||||||
营业损失 |
(580,405 ) |
(1,965,558 ) |
(2,743,425 ) |
(6,102,483 ) |
||||||||||||
其他收入(费用) |
||||||||||||||||
利息收入 |
2 |
5,917 |
53 |
5,944 |
||||||||||||
外汇交易损失 |
- |
- |
- |
投资活动产生的现金流量净额:(15,000美元) ) |
||||||||||||
贷款手续费的摊销。 |
(60,000 ) |
- |
(64,000 ) |
- |
||||||||||||
可转换债券公允价值变动 |
- |
167,283 |
- |
264,706 |
||||||||||||
利息支出 |
(98,556 ) |
(45,655 ) |
(108,823 ) |
(159,380 ) |
||||||||||||
其他总收益(费用),净额 |
(158,554 ) |
127,545 |
(172,770 ) |
96,270 |
||||||||||||
计提所得税前亏损 |
(738,959 ) |
(1,838,013 ) |
(2,916,195 ) |
(6,006,213 ) |
||||||||||||
所得税(税收利益)拨备 |
- |
$ |
- |
(142,811 ) |
||||||||||||
净亏损 |
$ |
(738,959 ) |
$ |
(1,837,824 ) |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||||||
综合亏损: |
||||||||||||||||
净亏损 |
$ |
(738,959 ) |
$ |
(1,837,824 ) |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||||||
其他综合收益(损失)– 外币翻译调整 |
89,933 |
35,364 |
51,878 |
127,394 |
||||||||||||
全面损失 |
$ |
(649,026 ) |
$ |
(1,802,460 ) |
$ |
(2,864,317 ) |
$ |
(6,021,630 ) |
||||||||
每股普通股基本和摊薄亏损 |
$ |
(0.39 ) |
$ |
(3.22 ) |
$ |
(1.69 ) |
$ |
(10.79 ) |
||||||||
加权平均股数: |
|
|
|
|
||||||||||||
基本和摊薄 |
1,889,694 |
570,753 |
1,726,716 |
569,882 |
||||||||||||
所有bio-key发行和未流通股份在所有期间反映出bio-key的1比18的股票合并,该合并于2023年12月21日生效。 |
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
September 30, |
December 31, |
|||||||
2024 |
2023 |
|||||||
(Unaudited) |
|
|||||||
ASSETS |
|
|
||||||
Cash and cash equivalents |
$ |
1,801,137 |
$ |
511,400 |
||||
Accounts receivable, net |
1,930,258 |
1,201,526 |
||||||
Due from factor |
49,018 |
99,320 |
||||||
Inventory |
386,944 |
445,740 |
||||||
Prepaid expenses and other |
382,866 |
364,171 |
||||||
Total current assets |
4,550,223 |
2,622,157 |
||||||
Equipment and leasehold improvements, net |
162,551 |
220,177 |
||||||
Capitalized contract costs, net |
430,596 |
229,806 |
||||||
Deposits and other assets |
7,975 |
- |
||||||
Operating lease right-of-use assets |
73,637 |
36,905 |
||||||
Intangible assets, net |
1,174,721 |
1,407,990 |
||||||
Total non-current assets |
1,849,480 |
1,894,878 |
||||||
TOTAL ASSETS |
$ |
6,399,703 |
$ |
4,517,035 |
||||
LIABILITIES |
|
|
||||||
Accounts payable |
$ |
1,564,654 |
$ |
1,316,014 |
||||
Accrued liabilities |
1,254,415 |
1,305,848 |
||||||
Note payable |
2,164,693 |
- |
||||||
Government loan – BBVA Bank, current portion |
141,854 |
138,730 |
||||||
Deferred revenue, current |
719,846 |
414,968 |
||||||
Operating lease liabilities, current portion |
24,545 |
37,829 |
||||||
Total current liabilities |
5,870,007 |
3,213,389 |
||||||
Deferred revenue, long term |
240,664 |
28,296 |
||||||
Deferred tax liability |
22,998 |
22,998 |
||||||
Government loan – BBVA Bank – net of current portion |
83,901 |
188,787 |
||||||
Operating lease liabilities, net of current portion |
49,091 |
- |
||||||
Total non-current liabilities |
396,654 |
240,081 |
||||||
TOTAL LIABILITIES |
6,266,661 |
3,453,470 |
||||||
Commitments and Contingencies |
||||||||
STOCKHOLDERS' EQUITY |
|
|
||||||
Common stock — authorized, 170,000,000 shares; issued and outstanding; 3,109,288 and 1,032,777 of $.0001 par value at September 30, 2024 and December 31, 2023, respectively |
311 |
103 |
||||||
Additional paid-in capital |
127,981,436 |
126,047,851 |
||||||
Accumulated other comprehensive loss |
74,699 |
22,821 |
||||||
Accumulated deficit |
(127,923,404 ) |
(125,007,210 ) |
||||||
TOTAL STOCKHOLDERS' EQUITY |
133,042 |
1,063,565 |
||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ |
6,399,703 |
$ |
4,517,035 |
||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key's 1-for-18 reverse stock split, which was effective December 21, 2023. |
bio-key international公司及其子公司 简明合并资产负债表 | ||||||||
9月30日, |
2023年12月31日, |
|||||||
2024 |
2023 |
|||||||
(未经审计) |
|
|||||||
资产 |
|
|
||||||
现金及现金等价物 |
$ |
1,801,137 |
$ |
511,400 |
||||
应收账款,净额 |
1,930,258 |
1,201,526 |
||||||
来自保理商的应收款 |
49,018 |
99,320 |
||||||
存货 |
386,944 |
445,740 |
||||||
预付费用及其他 |
382,866 |
364,171 |
||||||
总流动资产 |
4,550,223 |
2,622,157 |
||||||
|
162,551 |
220,177 |
||||||
资本化合同成本,净额 |
430,596 |
229,806 |
||||||
存款和其他资产 |
7,975 |
- |
||||||
经营租赁使用权资产 |
73,637 |
36,905 |
||||||
无形资产-净额 |
1,174,721 |
1,407,990 |
||||||
总非流动资产 |
1,849,480 |
1,894,878 |
||||||
资产总计 |
$ |
6,399,703 |
$ |
4,517,035 |
||||
负债 |
|
|
||||||
应付账款 |
$ |
1,564,654 |
$ |
1,316,014 |
||||
应计负债 |
1,254,415 |
1,305,848 |
||||||
应付票据 |
2,164,693 |
- |
||||||
政府贷款 – BBVA银行,当前部分 |
141,854 |
138,730 |
||||||
递延收入,流动 |
719,846 |
414,968 |
||||||
经营租赁负债,当前部分 |
24,545 |
37,829 |
||||||
总流动负债 |
5,870,007 |
3,213,389 |
||||||
递延收入,长期 |
240,664 |
28,296 |
||||||
递延所得税负债 |
22,998 |
22,998 |
||||||
政府贷款 – BBVA银行 – 净当前部分 |
83,901 |
188,787 |
||||||
经营租赁负债,净值超过流动资产 |
49,091 |
- |
||||||
总非流动负债 |
396,654 |
240,081 |
||||||
负债合计 |
6,266,661 |
3,453,470 |
||||||
承诺和事后约定 |
||||||||
股东权益 |
|
|
||||||
普通股——授权170,000,000股;已发行并流通;截至2024年9月30日和2023年12月31日,各为3,109,288股和1,032,777股,面值为0.0001美元。 |
311 |
103 |
||||||
追加实收资本 |
127,981,436 |
126,047,851 |
||||||
累计其他综合损失 |
74,699 |
22,821 |
||||||
累积赤字 |
(127,923,404 ) |
(125,007,210 ) |
||||||
股东权益合计 |
133,042 |
1,063,565 |
||||||
负债合计及股东权益总计 |
$ |
6,399,703 |
$ |
4,517,035 |
||||
所有BIO-key的已发行和未变现股份,在所有时期均反映了BIO-key的1比18的股票逆向拆分,该拆分于2023年12月21日生效。 |
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | ||||||||
Nine Months Ended September 30, |
||||||||
2024 |
2023 |
|||||||
CASH FLOW FROM OPERATING ACTIVITIES: |
|
|
||||||
Net loss |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||
Adjustments to reconcile net loss to net cash used for operating activities: |
|
|
||||||
Depreciation |
69,115 |
38,213 |
||||||
Amortization of intangible assets |
233,269 |
217,978 |
||||||
Change in fair value of convertible note |
- |
(264,706 ) |
||||||
Amortization of capitalized contract costs |
128,953 |
126,057 |
||||||
Amortization of Note Payable |
64,000 |
- |
||||||
Reserve for inventory |
(98,875 ) |
2,500,000 |
||||||
Operating leases right-of-use assets |
(58,950 ) |
146,890 |
||||||
Share and warrant-based compensation for employees and consultants |
162,614 |
163,584 |
||||||
Stock based directors' fees |
9,003 |
39,006 |
||||||
Deferred income tax benefit |
- |
(20,000 ) |
||||||
Bad debts |
- |
550,000 |
||||||
Change in assets and liabilities: |
|
|
||||||
Accounts receivable |
(398,753 ) |
(434,989 ) |
||||||
Due from factor |
50,302 |
(13,072 ) |
||||||
Capitalized contract costs |
(329,743 ) |
(107,336 ) |
||||||
Deposits |
(7,975 ) |
- |
||||||
Inventory |
58,796 |
145,156 |
||||||
Prepaid expenses and other |
(18,695 ) |
(51,831 ) |
||||||
Accounts payable |
248,640 |
488,417 |
||||||
Accrued liabilities |
(51,433 ) |
327,131 |
||||||
Income taxes payable |
- |
62,811 |
||||||
Deferred revenue |
517,246 |
128,253 |
||||||
Operating lease liabilities |
(60,827 ) |
(154,460 ) |
||||||
Net cash used in operating activities |
(2,399,508 ) |
(2,261,922 ) |
||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
||||||
Capital expenditures |
(23,047 ) |
- |
||||||
Net cash used in investing activities |
(23,047 ) |
- |
||||||
CASH FLOW FROM FINANCING ACTIVITIES: |
|
|
||||||
Proceeds from Note Payable |
2,000,000 |
- |
||||||
Offering costs |
(147,862 ) |
(25,434 ) |
||||||
Proceeds for exercise of warrants |
1,908,099 |
- |
||||||
Receipt of cash from Employee stock purchase plan |
1,939 |
13,934 |
||||||
Repayment of government loan |
(101,762 ) |
(113,885 ) |
||||||
Net cash used in financing activities |
3,660,414 |
(125,385 ) |
||||||
Effect of exchange rate changes |
51,878 |
58,871 |
||||||
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
1,289,737 |
(2,328,436 ) |
||||||
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
511,400 |
2,635,522 |
||||||
CASH AND CASH EQUIVALENTS, END OF PERIOD |
$ |
1,801,137 |
$ |
307,086 |
||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key's 1-for-18 reverse stock split, which was effective December 21, 2023. |
bio-key international公司及其子公司 现金流量表简明综合报表 (未经审计) | ||||||||
截至9月30日的九个月 |
||||||||
2024 |
2023 |
|||||||
经营活动产生的现金流量: |
|
|
||||||
净亏损 |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||
调整以将净亏损调节为经营活动现金流的净现金支出: |
|
|
||||||
折旧费 |
69,115 |
38,213 |
||||||
无形资产摊销 |
233,269 |
217,978 |
||||||
可转换债券公允价值变动 |
- |
(264,706 ) |
||||||
资本化合同成本的摊销 |
128,953 |
126,057 |
||||||
应付票据的摊销 |
64,000 |
- |
||||||
库存储备 |
(98,875 ) |
2,500,000 |
||||||
经营租赁权使用资产 |
(58,950 ) |
146,890 |
||||||
基于股票和认股权证的员工及顾问补偿 |
162,614 |
163,584 |
||||||
基于股票的董事费 |
9,003 |
39,006 |
||||||
递延所得税收益 |
- |
(20,000 ) |
||||||
坏账 |
- |
550,000 |
||||||
资产和负债的变动: |
|
|
||||||
应收账款 |
(398,753 ) |
(434,989 ) |
||||||
来自保理商的应收款 |
50,302 |
(13,072 ) |
||||||
资本化的合同成本 |
(329,743 ) |
(107,336 ) |
||||||
押金 |
(7,975 ) |
- |
||||||
存货 |
58,796 |
145,156 |
||||||
预付费用及其他 |
(18,695 ) |
(51,831 ) |
||||||
应付账款 |
248,640 |
488,417 |
||||||
应计负债 |
(51,433 ) |
327,131 |
||||||
应付所得税 |
- |
62,811 |
||||||
递延收入 |
517,246 |
2,025,845 |
||||||
营运租赁负债 |
(60,827 ) |
(154,460 ) |
||||||
用于经营活动的净现金 |
(2,399,508 ) |
(2,261,922 ) |
||||||
投资活动产生的现金流量: |
|
|
||||||
资本支出 |
(23,047 ) |
- |
||||||
投资活动中使用的净现金 |
(23,047 ) |
- |
||||||
融资活动现金流量: |
|
|
||||||
应付票据的收益 |
2,000,000 |
- |
||||||
发行成本 |
(147,862 ) |
(25,434 ) |
||||||
行使warrants的收益 |
1,908,099 |
- |
||||||
员工股票认购计划收到的现金 |
1,939 |
13,934 |
||||||
政府贷款偿还 |
(101,762 ) |
(113,885 ) |
||||||
融资活动所使用的净现金 |
3,660,414 |
(125,385 ) |
||||||
汇率变动的影响 |
51,878 |
58,871 |
||||||
现金及现金等价物净增减额 |
1,289,737 |
(2,328,436 ) |
||||||
期初现金及现金等价物余额 |
511,400 |
2,635,522 |
||||||
期末现金及现金等价物余额 |
$ |
1,801,137 |
$ |
307,086 |
||||
所有bio-key股份的发行和流通股份反映了bio-key的1比18的股票合并,该合并于2023年12月21日生效。 |